Curriculum Vitae

PROF. DR. ROSMAWATI BINTI MOHAMED

Honorary Professor
  • Department of Medicine
    Faculty of Medicine
  • rosmohamed

AREAS OF EXPERTISE

  • HEPATOLOGY
    Viral Hepatitis, Hepatitis B, Hepatitis C, Fatty Liver, Hepatocellular Carcinoma

ACADEMIC QUALIFICATION

  • MD(Birmingham University,UK)(1997), (Hepatology)
    Birmingham University, Birmingham, UK
  • MIntMed(UM)(1992), (Hepatology)
    Universiti Malaya (UM)
  • MRCP(UK)(1991), (Internal Medicine)
    Royal College of Physicians of Edinburgh, United Kingdom
  • MBBS(Monash University)(1985), (Medicine and Surgery)
    Monash University, Australia

ADMINISTRATIVE DUTIES

  • Wakil GantiTetap Dekan
    26 Jan 2018 - 25 Jan 2021 (University Malaya)
  • Coordinator
    12 Nov 2017 - 31 Dec 2018 (Department of Medicine, Faculty of Medicine)
  • Deputy Dean
    01 Sep 2009 - 22 Apr 2011 (Dean's Office, Faculty of Medicine)
  • Deputy Dean of Higher Degree
    01 Sep 2009 - 21 Apr 2011 (Faculty)
  • Deputy Dean
    01 Sep 2007 - 31 Aug 2009 (Dean's Office, Faculty of Medicine)
  • Deputy Dean of Research
    05 Apr 2004 - 31 Aug 2009 (Dean Office, Faculty of Medicine)
  • Deputy Dean
    01 Sep 2006 - 31 Aug 2007 (Dean's Office, Faculty of Medicine)
  • Deputy Dean
    01 Apr 2006 - 31 Aug 2006 (Dean's Office, Faculty of Medicine)
  • Deputy Dean
    05 Apr 2004 - 31 Mar 2006 (Dean's Office, Faculty of Medicine)

MEMBERSHIPS

  • COALITION TO ERADICATE VIRAL HEPATITIS IN ASIA PACIFIC (CEVHAP), CHAIRPERSON
    Since 2018 (International)
  • ACADEMY OF MEDICINE MALAYSIA, PRESIDENT/ CHIEF
    Since 2017 (National)
  • ACADEMY OF MEDICINE OF MALAYSIA, COUNCIL MEMBER
    Since 2007 (National)

AWARD AND STEWARDSHIP

  • 2nd Best Poster Award
    Asian-Pacific Association for the Study of the Liver (APASL) , 2018 (International)
  • Fellow, Academy of Medicine, Singapore
    Academy of Medicine, Singapore, 2017 (International)
  • Poster of Distinction
    Asian Pacific Association for The Study of the Liver, 2014 (International)
  • KHIDMAT SETIA 20 AWARD
    University of Malaya, 2011 (University)
  • Travel Award, NASH2010
    Ninth Japan Society of Hepatology Single Topic Conference, 2010 (International)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2007 (University)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2006 (University)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2004 (University)

PUBLICATIONS

Article in Journal
  1. Polaris Observatory Collaborators. The case for simplifying and using absolute targets for viral hepatitis elimination goals. J Viral Hepat. 2021;28(1):12 19
  2. Ting YW, Kong AS, Zain SM, Chan WK, Tan HL, Mohamed Z, Pung YF, Mohamed R. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort. Clin Mol Hepatol. 2021 Feb 23. doi: 10.3350/cmh.2020.0162.
  3. Wong SW, Ting YW, Yong YK, Tan HY, Muttiah B, Riazi B, Chook JB, Tee KK, Larsson M, Shankar EM, Mohamed R. Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection. Scand J Clin Lab Invest 2021; 81(2):147-159.
  4. Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020 Sep;55(9):811-823. doi: 10.1007/s00535-020-01698-4
  5. Li PK, Bavanandan S, Mohamed R,et al. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Report 2020;5(8):1129-1138
  6. Lindsey Hiebert, Amirah Azzeri, Maznah Dahlui, Robert Hecht, Rosmawati Mohamed Fatiha Hana Shabaruddin & Scott A. McDonald. 2020: Estimating of the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method, Substance Use & Misuse, DOI: 10.1080/10826084.2019.1708943
  7. Raihan R, Akbar SMF, Al Mahtab M, Khan MSI, Tabassum S, Tee KK, Mohamed R. Increased proinflammatory cytokine production by chronic hepatitis B patients with mutant hepatitis B virus: plausible mechanisms underlying severe liver diseases in these patients. Viral Immunol 2020; 33(7):530-534.
  8. Shamsul Mohd Zain, Hwa Li Tan, Zahurin Mohamed, Wah-Kheong Chan, Sanjiv Mahadeva, Roma Choudhury Basu, Rosmawati Mohamed. Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients. Journal of Gastroenterology and Hepatology 2020;4(6):1155-1161. doi: 10.1002/jgh3.12414
  9. Wong, S. W., Chan, W. K., & Mohamed, R. (2020). Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. Journal of viral hepatitis, 27(12), 1297-1305.
  10. XZ Wong, CC Gan, R Mohamed, R Yahya, S Ganapathy, SS Tan, SK Lim (2020). Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients. BMC Nephrol, Nov 13;21(1):480.
  11. Chook JB, Ngeow YF, Tee KK, Lee JWT, Mohamed R. Increased Coffee Intake Reduces Circulating HBV DNA and HBsAg Levels in HBeAg-Negative Infection: A Cohort Study. Viruses. 2019 Sep 1;11(9). pii: E808. doi: 10.3390/v11090808
  12. Gane EJ, Charlton MR, Mohamed R, et al. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat. 2019;27(5):466-475. doi: 10.1111/jvh.13244
  13. Gane EJ, Charlton MR, Mohamed R, et al. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat. 2019;27(5):466-475doi: 10.1111/jvh.13244.
  14. Hiebert L, Hecht R, Soe-Lin S, Mohamed R, Shabaruddin FH, Syed Mansor SM, Dahlui M, Azzeri A, McDonald SA (2019) A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs. Value in Health Regional Issues 18: 112-120
  15. Lindsey Hiebert, Amirah Azzeri, Maznah Dahlui, Robert Hecht, Rosmawati Mohamed Fatiha Hana Shabaruddin & Scott A. McDonald. 2020: Estimating of the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method, Substance Use & Misuse, DOI: 10.1080/10826084.2019.1708943
  16. Mohamed R, Shabaruddin FH, Azzeri A, McDonald SA, Dahlui M (2019) Hepatitis C elimination by 2030 in Malaysia: an achievable goal? Journal of Virus Eradication 5:253
  17. Raihan R, Akbar SMF, Al Mahtab M, Takahashi K, Masumoto J, Tabassum S, Tee KK, Mohamed R. Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh. PLoS One 2019; 14(6):e0218744.
  18. Schr eder SE, Pedrana A, ScottN, et al. Innovative Strategies for the Elimination of Viral Hepatitis at a National Level: A Country Case Series. Liver Int 2019 Oct;39(10):1818-1836
  19. Wei L, Lim SG, Xie Q, V n KN, Piratvisuth T, Huang Y, Mohamed R, Hou JL, Jia J. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1.
  20. Yi Wen Ting, Sui Weng Wong, Azriyanti Anuar Zaini, Rosmawati Mohamed, Muhammad Yazid Jalaludin. Metabolic syndrome is associated with advanced liver fibrosis among pediatric patients with non-alcoholic fatty liver disease. Front. Pediatr. 7:491(1-10)
  21. Azzeri A, Shabaruddin FH, , Tan SS, Dahlui M, McDonald SA, Kamarulzaman A, Mohamed R. CLINICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C INFECTION AT INITIAL PRESENTATION TO TERTIARY CARE IN AN ASIAN MIDDLE-INCOME COUNTRY
  22. Barathan M, Mohamed R, Yong YK, Kannan M, Vadivelu J, Saeidi A, Larsson M, Shankar EM. Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells. 2018 Oct 12;7(10). pii: E165. doi: 10.3390/cells7100165
  23. Hyper-Expression of PD-1 Is Associated with the Levels of Exhausted and Dysfunctional Phenotypes of Circulating CD161++TCR iV 7.2+ Mucosal-Associated Invariant T Cells in Chronic Hepatitis B Virus Infection Yean K. Yong, Alireza Saeidi, Hong Y. Tan, Mohamed Rosmawati, Philip F. Enstr m, Rami Al Batran, V. Vasuki, Indranil Chattopadhyay, Amudhan Murugesan, Ramachandran Vignesh, Adeeba Kamarulzaman, Jayakumar Rajarajeswaran, Abdul W. Ansari, Jamuna Vadivelu, James E. Ussher, Vijayakumar Velu, Marie Larsson, Esaki M. Shankar Front Immunol. 2018; 9: 472. Published online 2018 Mar 19. doi: 10.3389/fimmu.2018.0047
  24. Lim SG, Phyo WW, Shah SR, Win KM, Hamid S, Piratvisuth T, Tan SS, Dan YY, Lee YM, Ahmed T, Yang WL, Chen KP, Kamat M, Wadhawan M, Madan K, Mehta R, Shukla A, Dhore P, Eapen CE, Abraham P, Tyagi S, Koshy A, Bwa AH, Jafri W, Abid S, Arisar FAQ, Tanwandee T, Yin TP, Tee HP, Hj Md Said RB, Goh KL, Ho SH, Mohamed R, Abu Bakar N. Findings from a large Asian chronic hepatitis C real-life study. J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
  25. McDonald SA, Azzeri A, Shabaruddin FH, Dahlui M, Tan SS, Kamarulzaman A, Mohamed R. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040. Appl Health Econ Health Policy. 2018 Aug 25. doi: 10.1007/s40258-018-0425-3.
  26. Prevalence of HLA-DQ Alleles and Haplotypes in Patients with Hepatitis B Infection. American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS). (2018) Volume 43, No 1, pp 159-168. ISSN (Online) 2313-4402
  27. Raihan R, Azzeri A, H Shabaruddin F, Mohamed R. Hepatocellular Carcinoma in Malaysia and Its Changing Trend. Euroasian J Hepatogastroenterol. 2018;8(1):54-56. doi: 10.5005/jp-journals-10018-1259
  28. Barathan M, Mohamed R, et al. CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cell Immunol. 2017 Mar;313:1-9
  29. Behnaz Riazalhosseini, Rosmawati Mohamed, Devi Apalasamy, Mbongo Langmia, Zahurin Mohamed: Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B. Revista da Sociedade Brasileira de Medicina Tropical 04/2017; 50(2):161-166., DOI:10.1590/0037-8682-0416-2016
  30. Blach S, and The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyLancet Gastroenterol Hepatol 2017;2:161 76
  31. Chan HLY, Chen CJ, mede O, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm. J Viral Hepat. 2017;24(Suppl. 2):25-43. doi.org/10.1111/jvh.12760
  32. Yong YK, Tan HY, Saeidi A, Rosmawati M, et al. Decrease of CD69 levels on TCR V 7.2+CD4+ innate-like lymphocytes is associated with impaired cytotoxic functions in chronic hepatitis B virus-infected patients. Innate Immun. 2017 Jul;23(5):459-467
  33. 1.Hwa-li Tana, Rosmawati Mohamed, Zahurin Mohamed, Shamsul Mohd Zain. Phosphatidylethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of non-alcoholic fatty liver disease: Evidence from meta-analysis. Pharmacogenetics and Genomics 2016 Feb;26(2):88-95
  34. Alsalahi A, Alshawsh MA, Mohamed R, Alyousefi NA, Alshagga MA, Shwter AN, Al-Maqtari A, Ahmed RH, Mohamed Z. Conflicting Reports on the Role of the Glycemic Effect of Catha edulis (Khat): A Systematic Review and Meta-analysis. J Ethnopharmacol. 2016 Jun 20;186:30-43
  35. Behnaz Riazalhosseini, Zahurin Mohamed, Yamunah D Apalasamy, Rosmawati Mohamed. Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B. Pharmacogenetics and Genomics 2016;26(2):74-9.3.48
  36. Suzanne Wait, Emily Kell, Saeed Hamid, David H Muljono, Jose Sollano, Rosmawati Mohamed, Samir Shah, Mamun-Al-Mahtab, Zaigham Abbas, Jennifer Johnston, Tawesak Tanwandee, Jack Wallace (2016). Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. Lancet Gastroenterol Hepatol, 1, 248 55.
  37. Barathan M, Gopal K, Mohamed R, Ellegard R, Saeidi A, Vadivelu J, Ansari AW, Rothan HA, Ravishankar Ram M, Zandi K, Chang LY, Vignesh R, Che KF, Kamarulzaman A, Velu V, Larsson M, Kamarul T, Shankar EM. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis. 2015 Jan 11. [Epub ahead of print]
  38. Lim SG, Amarapurkar DN, Chan HLY, et al. Reimbursement policies in the Asia-Pacific for CHRONIC Hepatitis B. Hepatology International 2015;9(1): 43-51
  39. McDonald SA, Dahlui M, Mohamed R, Naning H, Shabaruddin FH, et al. (2015) Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia. PLoS ONE 10(6): e0128091. doi: 10.1371/journal.pone.0128091
  40. Ahmad Najib Azmi, Soek-Siam Tan, Rosmawati Mohamed. Practical Approach In Hepatitis B e Antigen-negative Individuals To Identify Treatment Candidates. World Journal of Gastroenterology 2014
  41. Zain SM, Mohamed Z, Rosmawati Mohamed. A common variant in the glucokinase regulatory gene rs780094 and risk of non-alcoholic fatty liver disease: A meta- analysis. J Gastroenterol Hepatol. 2014 Aug 28. doi: 10.1111/jgh.12714
  42. Zain SM, Rosmawati M, Cooper D, Razali R, Rampal S, Mahadeva S, Chan WK, Anwar A, Nurul SMR, Anis SF, Cheah PL, Basu RC, Tan HL, Mohamed Z. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non- alcoholic fatty liver disease. PLOS ONE 2014;9 (4):e95604 , PLOS ONE 9(4):E95604 APRIL 2014. Impact Factor: 3.53. DOI: 10.1371/journal.pone.0095604
  43. Chan WK, Tan SS, Rosmawati Mohamed. Stopping Therapy in HBeAg Negative Disease. Curr Hepatitis Rep DOI 10.1007/s11901-013-0167-5
  44. KP,Ng, YF Ngeow, Rozainah K, Rosmawati M. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia 2013:68;144-147.
  45. Lye SH, Chahil JK, Bagali P, Alex L, Vadivelu J, Ahmad WA, Chan SP, Thong MK, Zain SM, Mohamed R (2013) Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with Familial hypercholesterolemia in Malaysia. PLOS ONE Volume 8 | Issue 4 | e60729
  46. Ng, Chirk Jenn, Low, W.Y., Wong, L.P., Mohd Ridwan Sudin, & Rosmawati Mohamed. 2013. Uncovering the experiences and needs of patiens with chronic Hepatitis B infection at diagnosis: A qualitative study. Asia Pac J Public Health 25(1): 32-40
  47. Shamsul Mohd Zain,*, Zahurin Mohamed,*, Sanjiv Mahadeva, Phaik-Leng Cheah, Sanjay Rampal, Kin-Fah Chin, Roma Choudhury Basu,** Hwa-Li Tan*, and Rosmawati Mohamed (2013). Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with PNPLA3 variant. Journal of Gastroenterology and Hepatology 2013;28(5):873-9. doi: 10.1111/jgh.12104. (Tier 2; Impact Factor = 2.87)
  48. Zain SM, Mohamed Z, Mahadeva S, Cheah PL, Rampal S, Chin KF, Basu RC, Tan HL, Mohamed R. The impact of LEPR variants on risk of non-alcoholic fatty liver disease and its interaction with PNPLA3 variant. J Gastroenterol Hepatol ;28(5):873-9.
  49. Zain SM, Mohamed Z, Mahadeva S, Rampal S, Basu RC, Cheah PL, Agus S, Rosmawati Mohamed. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non- alcoholic fatty liver disease in a multi- ethnic population. PLOS ONE 2013 Apr 8;8(4):e60729 (Tier 1 ISI-Cited Publication)
  50. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 2012
  51. Kok Beng Loh, MRAD1, Shaik Ismail Bux, MRAD1, Basri Johan Jeet Abdullah, FRCR1, Raja Amin Raja Mokhtar, FRCS2, Rosmawati Mohamed, MD3 Departments of 1Biomedical Imaging, 2Surgery and 3Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia. Hemorrhagic Cardiac Tamponade: Rare Complication of Radiofrequency Ablation of Hepatocellular Carcinoma http://dx.doi.org/10.3348/kjr.2012.13.5.643 pISSN 1229- 6929 eISSN 2005-8330 Korean J Radiol 2012;13(5):643-647
  52. Rosmawati Mohamed, Chirk J Ng, Wen T Tong, Suraya Z Abidin, Li P Wong, Wah Y Low. 2012. Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: A cross sectional study. BMC Public Health 12: 601.
  53. Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu RC, Mohamed Z.A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.Hum Genet. 2012 Jul;131(7):1145-52
  54. Chirk Jenn, Ng, Low, W.Y., Wong, Y.L, Sudin, M.R., Mohamed, R. 2011. Uncovering the experiences and needs of patients with chronic Hepatitis B infection at diagnosis: A qualitative study. Asia Pac J Public Health 2011. DOI: 10.1177/101053951141258
  55. Lui YY, Tsoi KK, Wong VW, Kao J-H, Hou J-L, Teo E-K, Rosmawati M, Piratvisuth T, Han K-H, Mihm U, Wong GL, Chan HL. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antiviral Therapy 2010;15:145-155
  56. Prevention of hepatocellular carcinoma in the Asia- Pacific region: Consensus statements. Farrell GC, Chan HL, Yuen MF, Amarapurkar DN, Chutaputti A, Fan JG, Hou JL, Han KH, Kao JH, Lim SG, Mohamed R, Sollano J, Ueno Y. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 2010;25 (4):657-663
  57. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Amarapurkar D, Han KH, Chan HL, Ueno Y; Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. (Collaborators: Farrell GC, Chan HL, Yuen MF, Amarapurkar DN, Chutaputti A, Fan JG, Hou JL, Han KH, Kao JH, Lim SG, Mohamed R, Sollano J, Ueno Y) J Gastroenterol Hepatol. 2009 Jun;24(6):955-61. Epub 2009 Mar 11.
  58. Hepatocellular carcinoma in the Asia pacific region. Yuen MF, Hou JL, Chutaputti A; (Collaborators: Farrell GC, Chan HL, Yuen MF, Amarapurkar DN, Chutaputti A, Fan JG, Hou JL, Han KH, Kao JH, Lim SG, Mohamed R, Sollano J, Ueno Y). Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. J Gastroenterol Hepatol. 2009 Mar;24(3):346-53. Epub 2009 Feb 12. Review
  59. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009 Aug;24 (8):1352-7.
  60. Ooi A, Tan S, Rosmawati M, Rahman NA, Othman RY. The full-length clone of Cucumber Green Mottle Mosaic Virus and its application as an expression system for Hepatitis B surface antigen. Journal of Biotechnology 2006 Feb 24;121(4):471-81
  61. Differential gene expression in colorectal cancer: quantitative analyses of angiogenesis genes and identification of potential candidates as molecular markers. JH Siong, AH Jennifer, SH Lim, M Rosmawati, M Sanjiv, LLC Ng, CW Law, CC Yeo. Medical Journal of Malaysia Vol. 60 Supplement A June 2005
  62. Rosmawati M. Aetiology and classification of acute liver failure. Med J Malaysia 2005;60:125-6.
  63. Rosmawati M, Desmond P, Dong-Jin Suh, Deepak A, Ed Gane, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterology and Hepatology 2004;19:958-969
  64. Lai CL, Rosmawati Mohamed, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002 Dec;123(6):1831-8
  65. Rosmawati Mohamed, Freeman JW, Guest PJ, Davies MK, Neuberger JM. Pulmonary gas exchange abnormalities in liver transplant candidates. Liver Transpl 2002 Sep;8 (9):802-8
  66. Yap SF, PW Wong YC Chen, M. Rosmawati. The frequency of Pre-core gene mutations in chronic Hepatitis B infection : A study of Malaysian subjects. Southeast Asian J Trop Med Public Health 2002;33:102-109
  67. Intrahepatic biloma: an unusual complication of cholangiocarcinoma treated endoscopically Author(s): Ranjeev, P; Goh, KL; Rosmawati, M, et al. Source: GASTROINTESTINAL ENDOSCOPY Volume: 50 Issue: 5 Pages: 711-713 Published: NOV 1999
  68. Rosmawati Mohamed, Hubscher SG, Mirza DF, Gunson B, Mutimer DJ. Post-transplantation chronic hepatitis in fulminant hepatic failure. Hepatology 1997;25(4):1003- 1007
  69. Rosmawati Mohamed, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23 (5):1128-1134
  70. Rosmawati Mohamed, Goh KL, Wong NW. Primary Biliary Cirrhosis. Med J Malaysia 1996;51:99-102
  71. Mirza DF, Rosmawati Mohamed, Mutimer DJ, McMaster P. Timing and candidacy for transplantation in acute liver failure: the European experience. Liver Transplantation 1995; 1 :182-186
Chapter in Books
  1. Text Book of Hepato-Gastroenterology

RESEARCH PROJECT

National
  1. 2013 - 2016, Merck Pharmaceuticals
    A multicenter open-label study to evaluate the safety and efficacy of PEG-IntronTM versus PEGASYSTM in subjects with HBeAg positive chronic hepatitis B and HBeAg negative chronic hepatitis B. ( Principal Investigator(PI))
  2. 2013 - 2016, MSD Pharmaceuticals
    A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy with MK- 3034 (SCH 503034)/ Boceprevir Combined with PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects with Chronic HCV Genotype 1 in Asia ( Principal Investigator(PI))
  3. 2013 - 2015, High Impact Research (HIR)
    Effect of coffee on viral activity and host immune response in chronic hepatitis B infection ( Principal Investigator(PI))
  4. 2013 - 2015, High Impact Research (HIR)
    Pharmocogenomics of Adverse Drug Reactions: Focus on Anti-tuberculosis Drug Induced Liver Injury (AT-DILI). 01/07/2013 to 31/07/2015 ( Principal Investigator(PI))
  5. 2012 - 2014, High Impact Research (HIR)
    Mechanisms of T cell dysfunctions in hepatitis C infection ( Consultant)
  6. 2012 - 2013, Monash University Malaysia
    Perception of Complimentary and Alternative Medicine (CAM)use in Hepatitis B- A Malaysian Perspective ( Consultant)
  7. 2006 - 2012, MOSTI
    Detection of Familial Hypercholesterolemia gene mutation amongst the Malaysian population ( Principal Investigator(PI))
  8. 2011 - 2012, High Impact Research (HIR)
    Pharmacogenomic studies in Non- Alcoholic Fatty Liver Disease (NAFLD) ( Consultant)
  9. 2007 - 2011, Geran Penyelidikan Universiti Malaya (UMRG)
    Proteomic and Genomic Analysis Of Colorectal Polyps And Cancer ( Principal Investigator(PI))
  10. 2009 - 2011, Geran Penyelidikan Universiti Malaya (UMRG)
    Variation across candidate genes and its role in the development of Non-alcoholic fatty liver disease and its complications in patients with metabolic syndrome ( Principal Investigator(PI))
  11. 2006, MOSTI
    Detection of Familial Hypercholesterolemia gene mutation amongst the Malaysian population ( PROJECT LEADER)
International
  1. 2018 - 2019, International Funding
    56136379HPB2001 A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection ( Principal Investigator(PI))
  2. 2017 - 2019, International Funding
    56136379HPB1001:A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of orally administered JNJ-56136379 to evaluate safety, tolerability and pharmacokinetics after single ascending doses and one multiple dose regimen in healthy subjects (Part I), and after multiple dose regimens in subjects with chronic hepatitis B(Part II) ( Principal Investigator(PI))
  3. 2008 - 2011, Pfizer
    A multinational, randomised, open-label, phase 3 study of sunitinib malate vs sorafenib in patients with advanced hepatocellular carcinoma. ( Consultant)
  4. 1996, Pharmaceutical Companies
    Treatment of Chronic Hepatitis B ( Principal Investigator(PI))
University
  1. 2007 - 2008, Fundamental Vote, University of Malaya, Kuala Lumpur
    Hepatitis B Survey: Patients Disease Profile and Their Quality of Life ( Principal Investigator(PI))

CONSULTANCY PROJECT

  • External Examiner for Gastroenterology Fellowship Exit Exam, Ministry of Health
    01 Jun 2011 - 01 Jun 2016 (National)
  • Asia-Pacific Hepatitis Advisory Board (Msd), Merck Sharp & Dohme (Asia) Ltd.
    01 Jun 2011 - 01 Jun 2016 (International)
  • Hepatitis C Advisory Board, Abbvie Pharmaceuticals
    01 Jun 2013 - 01 Jun 2015 (International)
  • Advisory Board Member, Novartis Pharmaceuticals Corporation
    01 May 2013 - 01 May 2015 (International)
  • Chronic Hepatitis B Guideline Working Party of The Asian-Pacific Association for The Study of The Liver, 2007-Ongoing, Asian-Pacific Association for the Study of the Liver
    01 Jan 2007 - 01 Jan 2015 (International)
  • Expert Working Group Meeting On Surveillance, Prevention and Management of Viral Hepatitis, WHO Regional Office for the Western Pacific
    01 Jun 2014 - 01 Jun 2014 (International)
  • Vertex Asia-Pacific Hepatitis Advisory Board, Merck Sharp & Dohme (Asia) Ltd.
    01 Jan 2012 - 01 Jan 2014 (International)
  • Improving Management of Viral Hepatitis Through Better Public Policies, Coalition to Eradicate Viral Hepatitis in the Asia-pacific
    01 Jun 2012 - 01 Jun 2012 (International)
  • Apasl 3rd Stc On Hbv 2012 Dhaka, ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
    01 Jun 2012 - 01 Jun 2012 (International)
  • Epidemiology of Hepatitis B in Asia-Pacific, APDW Federation
    01 Jun 2012 - 01 Jun 2012 (International)
  • External Examiner for B Medical Science, International Medical University
    01 Jun 2010 - 01 Jun 2010 (National)
  • Chronic Hepatitis B - Longterm Management Strategies, Glaxo-Smith Kline
    01 Jun 2008 - 01 Jun 2008 (National)
  • Asia Pacific Hepatitis B Management Advisory Board, Glaxo-Smith Kline
    01 Jun 2002 - 01 Jun 2008 (International)
  • Chronic Hepatitis B 2008, Novartis
    01 Jun 2008 - 01 Jun 2008 (National)

PAPER PRESENTED

PLENARY SPEAKER
  1. HBV in the Asia Pacific, 16th Asia Pacific Congress of Clinical Microbiology and Infection, APCCMI 2016 Congress Organisers (International) (30 Nov 2016 - 03 Dec 2016)
INVITED SPEAKER
  1. Prevention of HCC and recurrence, 8th Annual Meeting of Asia-Pacific Alliance of Liver Diseases, 8th APALD Conference Secretariat (International) (02 Sep 2016 - 04 Sep 2016)
  2. Revisiting HCC: The 2016 evidence for preventing HCC and HCC recurrence, 4th ASEAN Perspective in Liver Diseases 2016 (APLD 2016), Thai Association for the Study of the Liver (THASL) (International) (20 Jan 2016 - 23 Jan 2016)
  3. CHRONIC VIRAL HEPATITIS B&C:WHAT IS THE LATEST GUIDELINE , 4th EAST COAST GASTRO-HEPATOLOGY CONFERENCE , Hospital HRPZII, Kota Bharu Kelantan  (National) (28 Apr 2014 - 30 Apr 2014)
  4. HBV management in special situations, Asian Pacific Digestive Week 2012 (International) (05 Dec 2012 - 08 Dec 2012)
  5. Epidemiology and Hepatitis B in Asia-Pacific, Asian Pacific Digestive Week 2012 (International) (05 Dec 2012 - 08 Dec 2012)
  6. Strategies to Optimize Response to Pegylated Interferon in HBeAg-positive Chronic Hepatitis B, APASL 3rd STC on HBV (International) (07 Oct 2012 - 08 Oct 2012)
  7. Aiming high to cure more patients through personalized healthcare, ASIAN PACIFIC PERSPECTIVE IN HEPATITIS (APPH) 2012, Thailand Association for the Study of Liver (International) (01 Jun 2012 - 02 Jun 2012)
  8. IMPROVING MANAGEMENT OF VIRAL HEPATITIS THROUGH BETTER PUBLIC POLICIES , Asian Pacific Association for the Study of the Liver (International) (16 Feb 2012 - 19 Feb 2012)
  9. Treating the hardest-to-cure: Treatment options for non-responders to peginterferon plus ribavirin today and in the future, Regional Expert Forum on the Liver and Kidney, Hanoi, Vietnam  (International) (20 Jun 2008 - 23 Jun 2008)
EVENT ORGANISER
  1. Driving Research Innovation Towards Value Creation , Pecipta 2009 (International) (08 Oct 2009 - 10 Oct 2009)
  2. Personalizing Medicine - The A La Carte Approach, 42nd Malaysia-Singapore Congress Of Medicine, , Academy of Medicine, Malaysia (International) (01 Aug 2008 - 03 Aug 2008)
POSTER PRESENTER
  1. WHY DO PATIENTS WITH CHRONIC HEPATITIS B USE COMPLEMENTARY AND ALTERNATIVE MEDICINE? , 23RD CONFERENCE OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER, ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (International) (12 Mar 2014 - 15 Mar 2014)
  2. A qualitative study of medical doctors' views and experiences of the use of CAM chronic hepatitis B: , Gastro2013, World Congress of Gastroenterology.  (International) (21 Sep 2013 - 24 Sep 2013)
  3. DIFFERENTIALLY EXPRESSED PROTEINS IN COLORECTAL CANCER SERUM BY TWO-DIMENSIONAL GEL ELECTROPHORESIS , 5th Asean Society of Colorectal Surgeons Scientific Congress & 8th Malaysian Colorectal Conference Coloproctology 2010  (International) (05 Mar 2010 - 06 Aug 2010)
OTHERS
  1. CONDUCTING CLINICAL TRIALS IN MALAYSIA, Bio Malaysia 2006 Conference, Malaysian Biotechnology Corporation (BiotechCorp), the Malaysian BioIndustry Organisation (MBIO) AND MOSTI (National) (06 Dec 2006 - 08 Dec 2006)
  2. Anti HCV (+) HCV RNA (+) Normal ALT: Treat or Not to Treat, Asian-Pacific Digestive Week, Cebu City , Philippines (International) (27 Nov 2006)
  3. Treatment Strategies in Hepatitis B, Asian-Pacific Digestive Week (International) (26 Nov 2006 - 29 Nov 2006)
  4. Liver biopsy for Chronic Hepatitis B, 16th Conference of the Asian Pacific Association for the Study of the Liver,MANILA, PHILLIPINES, The Philippine Society of Gastroenterology (International) (05 Mar 2006 - 08 Mar 2006)

ACADEMIC/PROF. SERVICES

Contribution to external organisation
  1. (2018) Strategic and Technical Advisory Committee for Viral Hepatitis (STAC-HEP), World Health Organization, International
  2. (2002) Committee Member, Asia-Pacific Expert Committee on Hepatitis B Management, International

SUPERVISION

Postgraduate Student
PhD/ Doctoral
  1. (2012) GENETIC SUSCEPTIBILITY TO LIVER DISEASE PROGRESSION IN HBV INFECTED INDIVIDUALS, Behnaz Riazalhosseini
  2. (2011) Genetics and Proteomics : Towards Diagnosis and Prognosis of Non-Alcoholic Fatty Liver Disease, Tan Hwa Li
  3. (2009) Variation across candidate genes and its role in the development of non- alcoholic fatty liver disease and its complications in patients with metabolic syndrome, Shamsul Mohd Zain
  4. (2008) Novel Biomarkers for Predicting Clinical Outcomes of Chronic Hepatitis B Infection, JB Chook
  5. (2004) The full-length clone of Cucumber Green Mottle Mosaic Virus and its application as an expression system for Hepatitis B surface antigen, Ooi Aik Seng
Master
  1. (2010) Knowledge, attitude and practice among inflammatory bowel disease patients in UMMC, Dr. Nor Suraya binti Samsudin
  2. (2010) Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with Familial Hypercholesterolemia, LYE SAY HEAN
  3. (2010) Comparative Proteomic Analysis Of Corresponding Colon Cancer Plasma And Tissue Samples By Lc-Maldi Tandem Mass Spectrometry, CHOONG POH YEE
  4. (2009) Variations in the core promoter and precore regions of hepatitis B, Teo Ching Yee
  5. (2009) Methylation of Hepatitis B Virus Genome In Hepatitis B Virus Associated Hepatocellular Carcinoma, Ho Ka Yen
  6. (2008) Identification of proteins that are differentially expressed in the serum of patients with colorectal cancer, Mihat Munirah
  7. (2008) Favorable Effect Of Extracorporeal Shock Myocardial Revascularization (ESMR) On Left Ventricular (LV) Mechanical Dyssynchrony, Mohamad Nazrulhisham bin Mad Naser
  8. (2006) Cardiovascular Risk Factors in HIV patients on HAART at University Malaya Medical Centre, Dr. Suganthy a/p Robinson
  9. (2004) Delirium among elderly in the medical wards of a tertiary hospital in Malaysia, Dr. Sindhu Girish Chandran
  10. (2003) Association between exercise stress ECG, erectile dysfunction and cardiovascular risk factors, Dr. Shakeel Ahmed
  11. (1998) Hepatitis B and C Infection in Patients With Endstage Renal Disease On Renal Replacement Therapy, Dr. Chua Chin Jou
  12. (1997) Validation Of A New Rapid Hepatitis B Test For The Detection Of Surface and e Antigens in Whole Blood, Dr Anil Radhakrishnan
  13. (1997) The association between HLA genes and radiological disease severity in Malaysian patients with Rheumatoid Arthritis at University Malaya Medical Centre, Dr Asmah Mohd

TEACHING

Master
  1. (2018) MGF - Sarjana Perubatan Dalaman
  2. (2014) M MED - Internal Medicine
Bachelor
  1. (2018) 0000 - Ummp
  2. (2014) MBBS - Phase 3b
  3. (2013) MBBS - Phase 2
  4. (2013) MBBS - Phase 3a
  5. (2012) MBBS - Phase 3b

SOCIAL RESPONSIBILITY ACTIVITIES

  • Raising Awareness On Hepatitis and Liver Cancer Using a Film, (20 Sep 2018 - 31 Dec 2019)
  • Raising Public Awareness On Hepatitis C Via "How'S Your Blood" Campaign, (05 Jul 2018 - 30 Nov 2018)
  • Participated in The Who "Call to Action to Scale Up Global Hepatitis Response, (27 Mar 2014 - 28 Mar 2014)
  • Organising Chairperson for National Level Hepatitis Awareness in Malaysia, (10 Jan 2011)